Elanco Animal Health Incorporated

ELAN Healthcare Drug Manufacturers Specialty & Generic

Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS grew 450.0%, free cash flow grew 35.6% and total debt fell 6.91%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

23.55 0.01 +0.04%
Market cap
$11.8B
P/E
0.0×
Fwd P/E
278×
Dividend yield
—
F-score
5/9
Altman Z
1.28
Beneish M
−2.68
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
5 5 5 6

+8 more TTM periods

ROE
(2.98%) (3.77%) (3.67%) 0.54%
ROA
(1.46%) (1.85%) (1.79%) 0.27%
ROIC
0.51% 0.35% 0.09% 1.21%
Return on Tangible Assets
(5.93%) (7.30%) (7.09%) 1.05%
Average Days of Receivables
83.76 86.08 72.77 77.52
Free Cash Flow per Share
0.76 0.63 0.57 0.74
Free Cash Flow
379.00 315.00 284.00 368.00
Other line items

Show all line items

Columns are period end dates